Since the 1918 influenza pandemic, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced the largest pandemic throughout the globe. SARS-CoV and the Middle East respiratory syndrome (MERS-CoV) ...Since the 1918 influenza pandemic, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced the largest pandemic throughout the globe. SARS-CoV and the Middle East respiratory syndrome (MERS-CoV) are both members of the Beta CoV. The coronavirus disease of 2019 (COVID-19) has terrible implications and is currently a serious health concern throughout the world. SARS-CoV-2 affects the respiratory system first since it is the major site of entrance into the patient, but it can also damage other systems. Aside from the typical respiratory problems, several COVID-19 patients develop gastrointestinal (GI) symptoms such as weight loss, vomiting, nausea, and diarrhea. SARS-CoV-2 may infect the GI system via the angiotensin-converting enzyme 2 (ACE2) receptor, and indications of a fecal-oral transmission pathway are growing. Globally, GI disorders (GIDs) are becoming a major source of morbidity in youth. The condition has a significant financial impact on healthcare systems and hurts people's lives;nonetheless, very little is documented about the condition's worldwide prevalence and incidence. Alterations in gut sensitivity, motility, microbiota, immunological function, and central nervous system processing are all factors that contribute to GIDs. GI malfunction results in changes in changes in gut bacteria as well as an elevation in inflammatory cytokines. As a result, recognizing GI symptoms that precede COVID-19 respiratory issues may be crucial for better early identification and treatment. In GI epithelial cells of the intestinal mucosa, ACE2 and transmembrane protease serine-type 2 were also discovered to be substantially expressed. SARS-CoV-2 may also infect and multiply in both GI and liver cells in a dynamic manner. These findings suggest that SARS-CoV-2 might be a viable target for the GI tract. This review focuses on the GI complications that arise due to COVID-19 and how the CoVs give rise to GI symptoms.展开更多
文摘Since the 1918 influenza pandemic, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced the largest pandemic throughout the globe. SARS-CoV and the Middle East respiratory syndrome (MERS-CoV) are both members of the Beta CoV. The coronavirus disease of 2019 (COVID-19) has terrible implications and is currently a serious health concern throughout the world. SARS-CoV-2 affects the respiratory system first since it is the major site of entrance into the patient, but it can also damage other systems. Aside from the typical respiratory problems, several COVID-19 patients develop gastrointestinal (GI) symptoms such as weight loss, vomiting, nausea, and diarrhea. SARS-CoV-2 may infect the GI system via the angiotensin-converting enzyme 2 (ACE2) receptor, and indications of a fecal-oral transmission pathway are growing. Globally, GI disorders (GIDs) are becoming a major source of morbidity in youth. The condition has a significant financial impact on healthcare systems and hurts people's lives;nonetheless, very little is documented about the condition's worldwide prevalence and incidence. Alterations in gut sensitivity, motility, microbiota, immunological function, and central nervous system processing are all factors that contribute to GIDs. GI malfunction results in changes in changes in gut bacteria as well as an elevation in inflammatory cytokines. As a result, recognizing GI symptoms that precede COVID-19 respiratory issues may be crucial for better early identification and treatment. In GI epithelial cells of the intestinal mucosa, ACE2 and transmembrane protease serine-type 2 were also discovered to be substantially expressed. SARS-CoV-2 may also infect and multiply in both GI and liver cells in a dynamic manner. These findings suggest that SARS-CoV-2 might be a viable target for the GI tract. This review focuses on the GI complications that arise due to COVID-19 and how the CoVs give rise to GI symptoms.
